The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. - Wikidata - wikimedia - TriplyDB

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q39722770

about

Role of the tumor microenvironment in mature B-cell lymphoid malignancies The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia Pharmacokinetic Interaction of Rifampicin with Oral Versus Intravenous Anticancer Drugs: Challenges, Dilemmas and Paradoxical Effects Due to Multiple Mechanisms BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia Targeting RTK Signaling Pathways in Cancer PI3K isoform-selective inhibitors: next-generation targeted cancer therapies PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)Idelalisib: The First-in-Class Phosphatidylinositol 3-Kinase Inhibitor for Relapsed CLL, SLL, and Indolent NHL Stromal Fibroblast in Age-Related Cancer: Role in Tumorigenesis and Potential as Novel Therapeutic Target Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies Ibrutinib (PCI-32765) in chronic lymphocytic leukemia Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia Novel agents in mantle cell lymphoma Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma How will B-cell-receptor-targeted therapies change future CLL therapy?The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib Signal transduction in the chronic leukemias: implications for targeted therapies Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease The tumor microenvironment shapes hallmarks of mature B-cell malignancies.The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells Idelalisib and rituximab in relapsed chronic lymphocytic leukemia Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12 Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapy PI3K and cancer: lessons, challenges and opportunities Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date.Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells.PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis

P2860

Q26748775-86E7229B-705C-40B3-A908-DEA5FB76FFE7 Q26751006-DF85944C-4398-4295-9BB7-B6CAEBDF2F4D Q26751444-FBCF3A35-8E5F-494D-9256-FFF8F72B136F Q26765624-AAAC4002-F46E-4926-BF1F-6DF877B95F72 Q26775506-A33477CA-8449-49BC-B622-D96F76C633EE Q26781278-8B7B8013-EB9B-4F81-A1FF-B92A4256B140 Q26781294-886028CF-36B1-4124-B413-ECB029ED55C6 Q26782633-619813F8-2F6E-41E0-9D59-F253277E8BD2 Q26795504-57EF16BA-44A9-4E9C-A2B7-D03BA7C914E8 Q26797288-ADF9AC44-64B4-4E1E-AF69-120FA32A541A Q26798062-1D5FF154-0423-4926-BE0E-67AEF8E482E3 Q26822700-0B95E098-FA89-4A67-B33F-1C652C6F6644 Q26852328-3DD12D07-2C80-45B6-B8AF-D6F860BA0803 Q26865645-284B4BAD-97B3-455F-B6CB-80B236274CFA Q26865760-45831EFB-1186-40D6-B074-4E8E94F0607F Q27006068-E10B0086-0708-4C18-B9FF-6E506FF77244 Q27011763-A79BA868-CA57-4830-B334-A903AD5E4B56 Q27013785-7CAE3C09-F9DD-4C94-BB18-0DA45046E4C4 Q27024187-E728917E-8280-47DE-8275-0E749CBA2D78 Q27024411-E15F73C1-3DD3-4273-9CF7-49E80BD0E594 Q27025812-D24CA74F-F224-4DB3-BD36-77C419240BA8 Q27026031-26A5BF7E-5A23-4F3E-AFFB-1944AACC3C0A Q27304652-88C7F1BC-13E3-407A-9333-CA66B4DAFDC6 Q27687567-9FE1477C-08EF-4970-8CAE-09A20081E5DE Q28070264-8ECF6D67-A1C5-4015-99A7-E8C68D2DAC37 Q28082086-4F4F6ABC-4063-4E70-9DFC-8249D3789BE0 Q28245018-9AE25561-26FE-42D1-B245-98867C3A80DE Q28306347-610E7B7C-2F47-4BE4-8AAD-EF2719E05F19 Q28484839-4DE9803A-CD9E-46CE-B28E-D75F03E5632F Q28649793-437C4886-F8D3-41F4-9C62-FB7FCB346BF7 Q29248893-B5800AC3-12F1-4260-849D-3317650462E0 Q30080017-3D1B22C3-FA92-4F12-BEB8-3CFCF7B920DE Q30365752-75842DBD-F7FB-4E3F-B50A-ED0BC4958599 Q31070331-E94F6D34-CC85-4C34-B4CF-F63439827A17 Q33413834-3FD8426A-E3E0-4EDD-B944-064CCE763E79 Q33558141-EEA7353E-72EB-42D9-87FF-F72C7751DCE4 Q33586239-554D7AC6-7434-457C-8480-E1AE580B61DC Q33690142-8717BB1A-A7CB-4A48-92FD-FE7235AF3EE4 Q33749652-AAD7C9F4-8418-49EA-BAF9-E957F92E7FE0 Q33785941-77524251-FAD8-4B41-991A-A5E6CF6D799C

P2860

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q39722770

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

The phosphoinositide 3'-kinase ...... chronic lymphocytic leukemia.

@en

The phosphoinositide 3'-kinase ...... chronic lymphocytic leukemia.

@nl

type

label

The phosphoinositide 3'-kinase ...... chronic lymphocytic leukemia.

@en

The phosphoinositide 3'-kinase ...... chronic lymphocytic leukemia.

@nl

prefLabel

The phosphoinositide 3'-kinase ...... chronic lymphocytic leukemia.

@en

The phosphoinositide 3'-kinase ...... chronic lymphocytic leukemia.

@nl

P1433

Q39722770-279C99DE-7C7D-4A89-A94E-3655C8B176EA

P1476

Q39722770-2F3D78DF-6E90-4B34-9D88-6CFB59791207

P2093

Q39722770-1E0B8D9D-C82F-4D01-9ABF-018BEA657FA2

Q39722770-34BCFBAE-A80D-435D-ACB0-37EBD16B3314

Q39722770-4A9E335C-5DE2-4C6A-AD24-3917BAD09528

Q39722770-51F68DBE-409F-494E-9892-422C9E3ACF1A

Q39722770-7C3842AB-F96D-4E88-8CDD-49C3D2101556

Q39722770-99C9262F-02FC-40B3-9DC0-A71ABB590786

Q39722770-BACD7B41-DC7B-4363-BB12-F0FAF0E42476

Q39722770-CFA5612A-0CD0-43F9-BFEC-D7F748654C50

P2860

Q39722770-0C313EA8-266D-4A84-B67F-06A8E959DB44

Q39722770-1A17F15F-E086-4D49-86E9-CBCBAC41CEEB

Q39722770-26A639A0-68A6-46AB-A52B-D85E0C9C0F82

Q39722770-28C763B7-2C8E-4719-B11D-6EF9249BBC42

Q39722770-488D6B2C-1319-4E72-884E-ACF0C951CDD9

Q39722770-4C984BA9-E2FC-4277-979F-932DD344DA41

Q39722770-5AB81208-379E-4603-B5A4-3317C928602E

Q39722770-5CC9311F-30A3-4427-B53C-85E266AE763E

Q39722770-5FF6EAFF-46EA-4DF4-B703-F7ED7314A3E6

Q39722770-64126653-E9B6-47F6-A218-9A0AB93C4794

P304

Q39722770-35F5ECB6-B4F6-4546-B3D8-882E39C0F23A

P31

Q39722770-CC6D9C77-40C5-45F3-9314-CB87D2F7C62E

P356

Q39722770-5909FB37-48DE-4B60-8B8C-232F3FA597A7

P407

Q39722770-484D058A-23AA-426C-9E10-368771910C43

P433

Q39722770-51587224-1A84-44D0-A7D9-A4011E27A41B

P478

Q39722770-1605FA97-9170-4F34-BFEC-B2D8E5C82757

P50

Q39722770-1C8F8CF7-ABC1-4B27-BB1D-266880B65A03

Q39722770-5C93326B-B1A3-47E4-A976-E56C126677C1

Q39722770-8BE1C11F-ED1F-4122-8D5C-6D7E9762E7B4

Q39722770-BC78C716-F1E9-4566-8849-253C9A383E37

P577

Q39722770-F38AB3D7-38EC-4C86-9EE0-288A063D6BB1

P5875

Q39722770-45E8C0CC-303E-470D-A08F-6587D3451580

P698

Q39722770-865EF093-B8D2-4342-960B-11B23170064A

P921

Q39722770-2A90713A-F132-4FDA-B2C8-C9589B95A41C

Q39722770-CF76673C-EA4E-46CD-BD05-29372E89BD41

P932

Q39722770-27CCD9AB-D6CF-451F-894E-0E73BA964218

P356

BLOOD-2011-05-352492

P1433

P1476

The phosphoinositide 3'-kinase ...... chronic lymphocytic leukemia.

@en

P2093

Albert Yu

http://www.w3.org/2001/XMLSchema#string

Brian J Lannutti

http://www.w3.org/2001/XMLSchema#string

Jan A Burger

http://www.w3.org/2001/XMLSchema#string

Julia Hoellenriegel

http://www.w3.org/2001/XMLSchema#string

Langdon L Miller

http://www.w3.org/2001/XMLSchema#string

Mariela Sivina

http://www.w3.org/2001/XMLSchema#string

Neill Giese

http://www.w3.org/2001/XMLSchema#string

Sarah A Meadows

http://www.w3.org/2001/XMLSchema#string

P2860

Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia

PI3K in lymphocyte development, differentiation and activation

A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation

Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice

Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22

Chronic lymphocytic leukemia

The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation

P304

3603-3612

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-05-352492

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Hagop Kantarjian

William G Wierda

Michael J. Keating

P577

2011-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51535122

http://www.w3.org/2001/XMLSchema#string

P698

21803855

http://www.w3.org/2001/XMLSchema#string

P921

P932

4916562

http://www.w3.org/2001/XMLSchema#string